Mereo BioPharma Group plc (MREO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Denise Vera Scots-Knight Ph.D.
|
Co-Founder, CEO & Executive Director | 686.84k | -- | 1959 |
|
Mr. Charles Edward Sermon
|
Co-Founder, General Counsel, Business Development & Company Secretary | 536.44k | -- | 1969 |
|
Ms. Christine Fox CPA
|
Chief Financial Officer | 497.2k | -- | 1981 |
|
Dr. John A. Lewicki Ph.D.
|
Chief Scientific Officer | -- | -- | 1952 |
|
Ms. Bal Lally
|
VP & Head of HR | -- | -- | -- |
|
Dr. Jackie Parkin
|
Senior VP & Therapeutic Head | -- | -- | 1958 |
|
Ms. Alexandra Hughes-Wilson
|
Chief of Patient Access & Commercial Planning | -- | -- | 1971 |
|
Mr. Bo Kara
|
Senior VP and Head of Pharmaceutical Development & CMC | -- | -- | -- |
|
Ms. Bharti Navsariwala
|
VP & Head of Regulatory Affairs | -- | -- | -- |
Mereo BioPharma Group plc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 39
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Corporate Governance
Upcoming Events
November 9, 2026 at 1:30 PM UTC
Mereo BioPharma Group plc Earnings Date
